ImmunoCellular Therapeutics (IMUC) 8-K ImmunoCellular Therapeutics Announces Third Quarter 2013 Financial Results

Condensed Balance Sheets
		9/30/2013		12/31/2012
		(unaudited)
Cash	$	29,433,560	$	26,216,668
Other current assets		401,962		714,508
Non current assets		103,511		88,025
	$	29,939,033	$	27,019,201
Current liabilities	$	1,067,529	$	1,098,307
Warrant liabilities		3,690,609		2,852,880
Shareholders' equity		25,180,895		23,068,014
	$	29,939,033	$	27,019,201
Condensed Statement of Operations (Unaudited)
		3 months		3 months		9 months		9 months
		ended		ended		ended		ended
		9/30/2013		9/30/2012		9/30/2013		9/30/2012
Revenue	$	-	$	-	$	-	$	-
Research and development		1,276,507		2,378,917		3,905,338		6,567,086
Stock based compensation		156,277		33,887		500,351		382,611
General and administrative		985,107		1,004,181		2,542,794		2,647,301
Loss before other expenses		(2,417,891)		(3,416,985)		(6,948,483)		(9,596,998)
Interest income		3,667		1,858		14,310		4,867
Financing expense		-		-		-		(368,524)
Change in fair value of warrant liabilities		(1,379,217)		2,777,500		(1,983,388)		(5,018,224)
Net loss	$	(3,793,441)	$	(637,627)	$	(8,917,561)	$	(14,978,879)